Effective August 15th, PHI has been admitted to trading on the OTCQB under the symbol "PHIXF". OTC Markets Group operates regulated markets for trading U.S. and international securities, offering global companies the opportunity to make their shares more accessible to U.S. investors. The move to OTCQB represents an important step for PHI, facilitating more transparent trading and catering to demand from U.S. investors.

PHI, already listed on the Spotlight Stock Market, can use its existing reporting standards to meet U.S. requirements on the OTCQB. This streamlined approach makes it easier for PHI to provide company information to U.S. investors. To qualify for trading on OTCQB, PHI has met financial standards, adhered to best practice corporate governance, and demonstrated compliance with applicable securities laws.

PHI's CEO, Patrik Eschricht, comments:

"We are excited to expand our market presence by listing on the OTCQB. This new platform offers our investors greater accessibility and visibility in the U.S. market, aligning with our mission to advance regenerative medicine. This dual listing is expected to enhance liquidity, provide greater value to our shareholders, and support the continued growth of PHI."

[image]